2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-145435
    SARS-CoV-2-IN-12 2721455-52-1 98%
    SARS-CoV-2-IN-12 (Compound 27) is a potent SARS-CoV-2-related 3C-like protease inhibitor (Ki=32.1 pM) for preventing SARS-CoV-2 viral replication and that could be useful in the research of COVID-19.
    SARS-CoV-2-IN-12
  • HY-145437
    N'-(2-Fluorophenyl)pyrazine-2-carbohydrazide 2881111-79-9 98%
    N'-(2-Fluorophenyl)pyrazine-2-carbohydrazide is a Ole1p desaturase inhibitor and antifungal agent.
    N'-(2-Fluorophenyl)pyrazine-2-carbohydrazide
  • HY-145439
    Colistin adjuvant-1 2862800-15-3 98%
    Colistin adjuvant-1 is a colistin adjuvant, shows increased colistin potentiation activity against Gram-negative bacteria. Colistin adjuvant-1 inhibits NF-κB with an IC50 of 0.209 μM.
    Colistin adjuvant-1
  • HY-145440
    Colistin adjuvant-2 2862800-23-3 98%
    Colistin adjuvant-2 is a colistin adjuvant, shows increased colistin potentiation activity against Gram-negative bacteria.
    Colistin adjuvant-2
  • HY-145638
    Xalnesiran 2538784-48-2
    Xalnesiran (RO7445482) is a small interfering RNA molecule that targets a conserved region of the
    hepatitis B virus (HBV) genome. Xalnesiran can be used for the research of chronic hepatitis B infection.
    Xalnesiran
  • HY-145641
    Crexavibart 2599039-61-7 98%
    Crexavibart (BMS-986413; C-144-LS) is an IgG1λ2 antibody that targets the SARS-CoV2 spike (S) glycoprotein receptor-binding domain.
    Crexavibart
  • HY-145642
    Masavibart 2640223-84-1 98%
    Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease.
    Masavibart
  • HY-145643
    Nepuvibart 2640224-48-0 98%
    Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease.
    Nepuvibart
  • HY-145704
    Antimalarial agent 8 2715222-97-0 98%
    Antimalarial agent 8 (Compound 7e) is a novel orally active class of antimalarials. Antimalarial agent 8 is potent in vitro against P. falciparum and is orally efficacious (40 mg/kg) in an in vivo mouse model of malaria.
    Antimalarial agent 8
  • HY-145713
    GS-8873 2241575-59-5 98%
    GS-8873 is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC50 of 4 nM. GS-8873 exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 causes neurofunctional deficits in rats and cynomolgus monkeys.
    GS-8873
  • HY-145812
    CRK12-IN-1 1990479-14-5 98%
    CRK12-IN-1 is a potent CRK12 inhibitor. CRK12-IN-1 is extremely potent against T.b. brucei and rapidly cytocidal, as well as equally potent against T. congolense and T. vivax (EC50 of 1.3 and 18 nM, respectively).
    CRK12-IN-1
  • HY-145814
    HSP90-IN-9 2765247-36-5 98%
    HSP90-IN-9 is a potent and selective HSP90 inhibitor. HSP90-IN-9 displays a fungicidal effect in a dose-dependent manner. HSP90-IN-9 inhibits fungal biofilm formation and fungal morphological changes after being combined with FLC. HSP90-IN-9 recovers FLC resistance by down-regulating the expression of related genes (ERG11, CDR1 and CDR2).
    HSP90-IN-9
  • HY-145842
    Encephalitic alphavirus-IN-1 98%
    Encephalitic alphavirus-IN-1 has antiviral activity for VEEV and EEEV with EC50s of 0.24 μM and 0.16 μM, respectively. Encephalitic alphavirus-IN-1 has robust mouse plasma stability, and no obvious cytotoxicity.
    Encephalitic alphavirus-IN-1
  • HY-145850
    EV-A71-IN-1 2413648-96-9 98%
    EV-A71-IN-1 is a human enterovirus A71 (EV-A71) capsid protein inhibitor with an EC50 of 0.27 μM against EV-A71. EV-A71-IN-1 is a capsid binder that blocks the interaction between the viral VP1 and the host receptor hSCARB2. EV-A71-IN-1 inhibits a series of different human enteroviruses without significant cytotoxicity (CC50>56.2 μM).
    EV-A71-IN-1
  • HY-145853
    GA-O-02 98%
    GA-O-02, a 18β-Glycyrrhetinic acid derivative, is a potent antimicrobial and anti-inflammatory agent. GA-O-02 exerts anti-inflammation through the inhibition of NO, pro-inflammatory cytokines and chemokines. GA-O-02 displays a high antimicrobial activity against Gram-positive bacteria.
    GA-O-02
  • HY-145854
    GA-O-06 98%
    GA-O-06, a 18β-Glycyrrhetinic acid derivative, is a potent antimicrobial and anti-inflammatory agent. GA-O-06 exerts anti-inflammation through the inhibition of NO, pro-inflammatory cytokines and chemokines. GA-O-06 displays a high antimicrobial activity against Gram-positive bacteria.
    GA-O-06
  • HY-145871
    BA38017 1333905-67-1 98%
    BA38017 is a potent HBV core protein assembly modulator. BA38017 inhibits HBV replication with an EC50 of 0.20 μM.
    BA38017
  • HY-145872
    HBV-IN-20 2750254-34-1 98%
    HBV-IN-20 is a potent and oral active HBV inhibitor with an EC50 of 0.46 µM. HBV-IN-20 is a typical type II CpAM (core protein assembly modulators).
    HBV-IN-20
  • HY-145873
    BI-10 2759037-58-4 98%
    BI-10 is an antifungal compound. BI-10 combined with Fluconazole can inhibit hyphal growth, result in ROS accumulation, and decrease mitochondrial membrane potential (MMP) as well as altering membrane permeability.
    BI-10
  • HY-145874
    Antibacterial agent 76 2902561-25-3 98%
    Antibacterial agent 76 (compound 9) is an antibacterial agent.
    Antibacterial agent 76
Cat. No. Product Name / Synonyms Application Reactivity